320 related articles for article (PubMed ID: 32320650)
1. GDF15 Induces an Aversive Visceral Malaise State that Drives Anorexia and Weight Loss.
Borner T; Wald HS; Ghidewon MY; Zhang B; Wu Z; De Jonghe BC; Breen D; Grill HJ
Cell Rep; 2020 Apr; 31(3):107543. PubMed ID: 32320650
[TBL] [Abstract][Full Text] [Related]
2. GDF15 Induces Anorexia through Nausea and Emesis.
Borner T; Shaulson ED; Ghidewon MY; Barnett AB; Horn CC; Doyle RP; Grill HJ; Hayes MR; De Jonghe BC
Cell Metab; 2020 Feb; 31(2):351-362.e5. PubMed ID: 31928886
[TBL] [Abstract][Full Text] [Related]
3. Growth differentiation factor 15 (GDF15) and semaglutide inhibit food intake and body weight through largely distinct, additive mechanisms.
Ghidewon M; Wald HS; McKnight AD; De Jonghe BC; Breen DM; Alhadeff AL; Borner T; Grill HJ
Diabetes Obes Metab; 2022 Jun; 24(6):1010-1020. PubMed ID: 35129264
[TBL] [Abstract][Full Text] [Related]
4. GDF15 acts synergistically with liraglutide but is not necessary for the weight loss induced by bariatric surgery in mice.
Frikke-Schmidt H; Hultman K; Galaske JW; Jørgensen SB; Myers MG; Seeley RJ
Mol Metab; 2019 Mar; 21():13-21. PubMed ID: 30685336
[TBL] [Abstract][Full Text] [Related]
5. The cytokine GDF15 signals through a population of brainstem cholecystokinin neurons to mediate anorectic signalling.
Worth AA; Shoop R; Tye K; Feetham CH; D'Agostino G; Dodd GT; Reimann F; Gribble FM; Beebe EC; Dunbar JD; Alexander-Chacko JT; Sindelar DK; Coskun T; Emmerson PJ; Luckman SM
Elife; 2020 Jul; 9():. PubMed ID: 32723474
[TBL] [Abstract][Full Text] [Related]
6. LPS induces rapid increase in GDF15 levels in mice, rats, and humans but is not required for anorexia in mice.
Patel AR; Frikke-Schmidt H; Bezy O; Sabatini PV; Rittig N; Jessen N; Myers MG; Seeley RJ
Am J Physiol Gastrointest Liver Physiol; 2022 Feb; 322(2):G247-G255. PubMed ID: 34935522
[TBL] [Abstract][Full Text] [Related]
7. Uniting GDF15 and GFRAL: Therapeutic Opportunities in Obesity and Beyond.
Mullican SE; Rangwala SM
Trends Endocrinol Metab; 2018 Aug; 29(8):560-570. PubMed ID: 29866502
[TBL] [Abstract][Full Text] [Related]
8. GFRAL is the receptor for GDF15 and is required for the anti-obesity effects of the ligand.
Yang L; Chang CC; Sun Z; Madsen D; Zhu H; Padkjær SB; Wu X; Huang T; Hultman K; Paulsen SJ; Wang J; Bugge A; Frantzen JB; Nørgaard P; Jeppesen JF; Yang Z; Secher A; Chen H; Li X; John LM; Shan B; He Z; Gao X; Su J; Hansen KT; Yang W; Jørgensen SB
Nat Med; 2017 Oct; 23(10):1158-1166. PubMed ID: 28846099
[TBL] [Abstract][Full Text] [Related]
9. The metabolic effects of GDF15 are mediated by the orphan receptor GFRAL.
Emmerson PJ; Wang F; Du Y; Liu Q; Pickard RT; Gonciarz MD; Coskun T; Hamang MJ; Sindelar DK; Ballman KK; Foltz LA; Muppidi A; Alsina-Fernandez J; Barnard GC; Tang JX; Liu X; Mao X; Siegel R; Sloan JH; Mitchell PJ; Zhang BB; Gimeno RE; Shan B; Wu X
Nat Med; 2017 Oct; 23(10):1215-1219. PubMed ID: 28846098
[TBL] [Abstract][Full Text] [Related]
10. The anorectic actions of the TGFβ cytokine MIC-1/GDF15 require an intact brainstem area postrema and nucleus of the solitary tract.
Tsai VW; Manandhar R; Jørgensen SB; Lee-Ng KK; Zhang HP; Marquis CP; Jiang L; Husaini Y; Lin S; Sainsbury A; Sawchenko PE; Brown DA; Breit SN
PLoS One; 2014; 9(6):e100370. PubMed ID: 24971956
[TBL] [Abstract][Full Text] [Related]
11. GFRAL is the receptor for GDF15 and the ligand promotes weight loss in mice and nonhuman primates.
Mullican SE; Lin-Schmidt X; Chin CN; Chavez JA; Furman JL; Armstrong AA; Beck SC; South VJ; Dinh TQ; Cash-Mason TD; Cavanaugh CR; Nelson S; Huang C; Hunter MJ; Rangwala SM
Nat Med; 2017 Oct; 23(10):1150-1157. PubMed ID: 28846097
[TBL] [Abstract][Full Text] [Related]
12. GDF15 mediates adiposity resistance through actions on GFRAL neurons in the hindbrain AP/NTS.
Tsai VW; Zhang HP; Manandhar R; Schofield P; Christ D; Lee-Ng KKM; Lebhar H; Marquis CP; Husaini Y; Brown DA; Breit SN
Int J Obes (Lond); 2019 Dec; 43(12):2370-2380. PubMed ID: 31152154
[TBL] [Abstract][Full Text] [Related]
13. Long-acting MIC-1/GDF15 molecules to treat obesity: Evidence from mice to monkeys.
Xiong Y; Walker K; Min X; Hale C; Tran T; Komorowski R; Yang J; Davda J; Nuanmanee N; Kemp D; Wang X; Liu H; Miller S; Lee KJ; Wang Z; Véniant MM
Sci Transl Med; 2017 Oct; 9(412):. PubMed ID: 29046435
[TBL] [Abstract][Full Text] [Related]
14. The GDF15-GFRAL pathway is dispensable for the effects of metformin on energy balance.
Klein AB; Nicolaisen TS; Johann K; Fritzen AM; Mathiesen CV; Gil C; Pilmark NS; Karstoft K; Blond MB; Quist JS; Seeley RJ; Færch K; Lund J; Kleinert M; Clemmensen C
Cell Rep; 2022 Aug; 40(8):111258. PubMed ID: 36001956
[TBL] [Abstract][Full Text] [Related]
15. Camptothecin effectively treats obesity in mice through GDF15 induction.
Lu JF; Zhu MQ; Xie BC; Shi XC; Liu H; Zhang RX; Xia B; Wu JW
PLoS Biol; 2022 Feb; 20(2):e3001517. PubMed ID: 35202387
[TBL] [Abstract][Full Text] [Related]
16. Anorexia-cachexia syndrome in hepatoma tumour-bearing rats requires the area postrema but not vagal afferents and is paralleled by increased MIC-1/GDF15.
Borner T; Arnold M; Ruud J; Breit SN; Langhans W; Lutz TA; Blomqvist A; Riediger T
J Cachexia Sarcopenia Muscle; 2017 Jun; 8(3):417-427. PubMed ID: 28025863
[TBL] [Abstract][Full Text] [Related]
17. Overview of growth differentiation factor 15 (GDF15) in metabolic diseases.
Li J; Hu X; Xie Z; Li J; Huang C; Huang Y
Biomed Pharmacother; 2024 Jul; 176():116809. PubMed ID: 38810400
[TBL] [Abstract][Full Text] [Related]
18. The MIC-1/GDF15-GFRAL Pathway in Energy Homeostasis: Implications for Obesity, Cachexia, and Other Associated Diseases.
Tsai VWW; Husaini Y; Sainsbury A; Brown DA; Breit SN
Cell Metab; 2018 Sep; 28(3):353-368. PubMed ID: 30184485
[TBL] [Abstract][Full Text] [Related]
19. Neutralization of GDF15 Prevents Anorexia and Weight Loss in the Monocrotaline-Induced Cardiac Cachexia Rat Model.
Albuquerque B; Chen X; Hirenallur-Shanthappa D; Zhao Y; Stansfield JC; Zhang BB; Sheikh A; Wu Z
Cells; 2022 Mar; 11(7):. PubMed ID: 35406637
[TBL] [Abstract][Full Text] [Related]
20. Neither GLP-1 receptors nor GFRAL neurons are required for aversive or anorectic response to DON (vomitoxin).
Patel AR; Frikke-Schmidt H; Sabatini PV; Rupp AC; Sandoval DA; Myers MG; Seeley RJ
Am J Physiol Regul Integr Comp Physiol; 2023 Mar; 324(5):R635-44. PubMed ID: 36912475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
